Para, Michael

Michael F. Para, MD
Pomerene Professor of Internal Medicine and Molecular Virology, Immunology, and Medical Genetics

N1143 Doan Hall
410 W. 10th Avenue
Columbus, Ohio 43210
(614) 293-5666
para.1@osu.edu

Dr. Para joined the faculty in 1981. He is Associate Dean for Clinical Research in the College of Medicine and Public Health. He has served as Chief of Staff of OSU Hospital and President of the College of Medicine’s Faculty Council. He has been a recipient of research awards from the American Lung Association, and NIH for work with herpes simplex, Legionella and HIV/AIDS.

Dr. Para was named Professor of the Year by the graduating medical school class of 1989 and has been awarded the Ohio Department of Health Directors AIDS Service Award in 1988, its AIDS Leadership Award in 1999 and the Healthcare Foundation Humanism in Medicine Award, 2001. He is a fellow of the American College of Physicians and the Infectious Disease Society of America. He currently serves on the Ohio Department of Health’s AIDS Drugs Assistance Program and Hemophilia Advisory Committee. He directs the AIDS Education and Training subunit at Ohio State and is co-principal investigator of the ACTG.

Special Interests
Dr. Para's clinical interest is in HIV and viral infections in compromised hosts. His research interest is in HIV therapeutics and vaccines, HIV management issues and HIV drug resistance. His recent work focuses on clinical trials of HIV therapeutics and vaccines.

Education
M.D., The Ohio State University, 1974

Post-doctoral Training
Internship/Residency: University of Chicago, 977

Subspecialty Training
Clinical, University of Chicago, 1979
Research, University of Chicago, 1981

Select Publications
Para MF, Kalish LA, Collier AC, Pollard R, Kumar P, Wallach F, Mintz L, and Drew WL for the VATS Study Group. Qualitative and Quantitative PCR Measures of CMV in Patients with Advanced HIV Infection Requiring Transfusion. J Acquire Immun Defic Syndrom 2001;26:320-325.

Smith BA, Neidig JL, Nickel JT, Mitchell GL, Para MF, Fass.RJ. Aerobic exercise training: Effects on parameters associated with fatigue, dyspnea, weight and body composition in HIV-1 infected adults. AIDS 2001;15:693-701

Para MF, Kalish LA, Collier AC, Murphy EL, Drew WL. Correlates of change in CMV viremia in Patients with Advanced HIV Infection Requiring Transfusion. J Infect Dis June 1, 2001; 183:1673-1678.

Albrecht MA, Bosch RJ, Dehlinger M, Katzenstein DA, Liou SH, Eron J, Para MF, Valdez H, Kessler H, Hammer SM. Virologic efficacy of nelfinavir and/or efavirenz with new nucleoside therapy in HIV-infected individuals with prior nucleoside analog exposure. N Engl J Med , August 9; 345:398, 2001.

Murphy EL, Kalish LA, Para MF, Kumar PN, Wallach FR, Collier AC, Assmann SF, Flanigan TP, Mintz L, Nemo GJ. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. July 3, 2001, Ann Intern Med 2001; 135:17—26.

Knudtson E, Para M, Boswell H, and Fan-Havard P. Drug rash, eosinophilia, systemic syndrome and renal toxicity with nevirapine-containing regimen in a pregnant patient with HIV. Obstet Gynecol  2003;101:1094-1097.

Picciano JF. Celum C, Whittington W, Buchbinder S, Bartholow B, McKirnan D, Mayer K. Para MF, Morris M. Sexual risk-taking behavior among phase III HIV vaccine efficacy trial participants and a control group: Project VISION. Submitted

Bartholow, Buchbinder S, Celum C,  Goli V, Koblin B, Para M, Marmor M, Novak RM, Mayer K, McKirnan DJ, Creticos C, Orozco-Cronin P, Popovic V,  and Mastro TD,  for the VISION/VAX004 Study HIV Sexual Risk Behavior over 36-Months of Follow-up in the World’s First HIV Vaccine Efficacy Trial. BN J Acquir Immune Defic Syndr  2005; 39:90-101

Smith PF,  DiCenzo R, Forrest A, Shelton M, Friedland G, Para MF, Pollard R, Fischl M, DiFrancesco R, Morse GD. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clinical Pharmacokinet 2005;44: 99-109

Gurwith,M, Gilbert P, Berman P, Flynn, N, Forthal D, Harro C, Heyward, W,  Hudgens M,  Judson F, Mayer K, Metch B, Para, MF, PopovicV, Self, S., and Francis DP, for the  rgp 120 HIV Vaccine Study Group*. Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection J Infect Dis. 2005 Mar 1;191(5):654-65

Morse GD, Rosenkranz S, Para MF, Segal Y DiFrancesco R Adams E Brizz B, Yarasheski K, Reichman R, and the ACTG 5043 Protocol Team. Amprenavir and Efavirenz Pharmacokinetics Before and After the Addition of Nelfinavir, Indinavir, Ritonavir or Saquinavir Antimicrob. Agents Chemother. 2005,49:3373-81

Fletcher C, Swindells S, Para M.  Nonnucleoside Analogue Reverse Transcriptase Inhibitors chapter in Antimicrobial Therapy and Vaccines Volume II Antimicrobial Agents 2005 editors Yu V, Edwards G, McKinnon P, Peloquin, Morse, Potoski. Page 817.

Rosenkranz SL, Yarasheski KE, Para MF, Reichman R, Morse GD, and the ACTG 5043 Protocol Team. Brief efavirenz plus protease inhibitor exposure raises serum lipids without affecting glycemic parameters in HIV-seronegative subjects. Submitted. To AIDS